Ind-Swift Laboratories Ltd

AGM Details

• AGM held 30 September 2026 at 03:05 PM via VC/OAVM.
• Meeting concluded at 03:29 PM IST; 15 minutes for e-voting.
• Shareholders present through VC/OAVM: 47.
• Remote e-voting window ran 27–29 September 2026.

Resolutions Presented

• Ordinary: Adopt Audited financial statements for year ended March 31, 2026; passed.
• Ordinary: Re-appointment by rotation of Navrattan Munjal; passed.
• Ordinary: Ratify remuneration to Cost Auditors for FY 2026-27; passed.
• Special: Appoint Amit Mathur as Independent Director; passed.

Director Changes

• Navrattan Munjal retires by rotation and seeks re-appointment.
• Amit Mathur appointed as Independent Director.

Auditor Appointments

• Remuneration to Cost Auditors ratified for FY 2026-27.

PAN/KYC/Nomination for physical holders

• Mandatory PAN, KYC, and Nomination updates for physical holders per SEBI circular.
• Non-updated folios may be barred from grievances or RTA services.
• From April 1, 2024, payments to be electronic if all details are provided.
• Forms ISR-1, ISR-2, SH-13, ISR-3, SH-14 required for updates.
• RTA contact: Alankit Limited, New Delhi (address provided in notice).
• Submission modes: IPV, hard copy, or e-sign, via Alankit.
• Date of notice: 28 September 2026; specimen letter attached.

Ind-Swift Laboratories Ltd — Trading Window closed from 1 October 2026 till forty-eight (48) hours after the declaration of Un-audited Standalone & Consolidated Financial Results for the quarter and half year ended 30 September 2026.

Meeting Details

• Date: 29 September 2026; Time: 01:00 P.M. IST
• Type: Group meeting; Mode: Virtual
• Organiser: Arihant Capital

Participants

• Key company management participants not specified in the filing

Purpose

• Analyst / institutional investor meeting for investor interaction

Transaction overview

• Target Company is Ind-Swift Laboratories Limited.
• Disclosing Party: Essix Biosciences Limited, promoter group of the target.
• Transaction Type: Allotment of fully convertible warrants through preferential issue.
• Date of allotment: September 17, 2026.

Pre-transaction holding

• Pre-transaction holding: Essix Biosciences Limited held 3,28,82,521 shares (37.92%).
• Promoter group PACs held 44,51,757 shares (5.13%), total 3,73,34,278 shares (43.06%).

Post-transaction holding

• Post-transaction holding: Essix Biosciences Limited held 3,28,82,521 shares (37.81%).
• PACs held 44,51,757 shares (5.12%), total post-hold 4,43,34,278 shares (42.93%).

Capital context

• Equity share capital before: Rs 86,71,15,580; after: Rs 86,96,15,580.
• Total diluted capital after: Rs 93,96,15,580.

Instrument details

• Warrants allotted: 70,00,000 Fully Convertible Warrants.
• Mode: Preferential Issue; Date: September 17, 2026.

Promoter FCW acquisition

• Essix Biosciences Limited and PACs acquired 70,00,000 Fully Convertible Warrants in Ind-Swift.
• Warrants will be convertible into an equivalent number of equity shares on a preferential basis.
• Date of allotment: 17 September 2026.
• Pre-acquisition promoter holdings: Essix 37.92%, PACs 5.13%.
• Post-issue promoter group voting cap: 42.93% via 4,43,34,278 shares.
• Post-issuance diluted voting capital: 9,39,61,558 shares; Rs 93,96,15,580.
• Equity share capital before/after: Rs 86,71,15,580 to Rs 86,96,15,580.

Capital / Securities

• Allotment of 70,00,000 Fully Convertible Warrants on a preferential basis to Essix Biosciences Limited.
• Issue price Rs 196 per warrant (premium Rs 186; 25% upfront Rs 49).
• Total warrant subscription price Rs 34,30,00,000.
• Allotment to Essix Biosciences Limited, promoter group.
• Meeting held 05:00 PM to 05:10 PM.
• Regulatory approvals: BSE and NSE in-principal approvals dated 16 September 2026.
• Shareholders approved on 5 August 2026.